Andrew Tsai
Stock Analyst at Jefferies
(4.85)
# 379
Out of 4,974 analysts
159
Total ratings
61%
Success rate
30.4%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Reiterated: Buy | $42 → $50 | $18.52 | +169.98% | 6 | Sep 8, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $110 | $72.38 | +51.98% | 12 | Aug 31, 2026 | |
| MRNA Moderna | Reiterated: Hold | $45 → $60 | $146.69 | -59.10% | 8 | Aug 19, 2026 | |
| NERV Minerva Neurosciences | Upgraded: Buy | $5 → $10 | $4.01 | +149.38% | 3 | Aug 14, 2026 | |
| ANRO Alto Neuroscience | Reiterated: Buy | $35 → $40 | $31.68 | +26.26% | 9 | Aug 13, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $65 | $40.25 | +61.49% | 6 | Aug 13, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $380 | $216.58 | +75.45% | 4 | Aug 11, 2026 | |
| BIIB Biogen | Reiterated: Buy | $255 | $217.36 | +17.32% | 9 | Jul 30, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $550 | $330.55 | +66.39% | 8 | Jun 30, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $18 | $14.54 | +23.80% | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $145 | $63.38 | +128.78% | 1 | Apr 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $100 | $58.19 | +71.85% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $30 | $20.92 | +43.40% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7.5 | $5.15 | +45.63% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.2432 | +270.07% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $29.60 | +1.35% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $13.15 | +143.35% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.95 | +153.16% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2.5 → $3 | $3.43 | n/a | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $0.85 | $1.98 | n/a | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8.5 | $5.34 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $41.49 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $44.00 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $7.47 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $4.44 | n/a | 4 | Sep 16, 2024 |
Dyne Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $42 → $50
Current: $18.52
Upside: +169.98%
BridgeBio Pharma
Aug 31, 2026
Reiterated: Buy
Price Target: $110
Current: $72.38
Upside: +51.98%
Moderna
Aug 19, 2026
Reiterated: Hold
Price Target: $45 → $60
Current: $146.69
Upside: -59.10%
Minerva Neurosciences
Aug 14, 2026
Upgraded: Buy
Price Target: $5 → $10
Current: $4.01
Upside: +149.38%
Alto Neuroscience
Aug 13, 2026
Reiterated: Buy
Price Target: $35 → $40
Current: $31.68
Upside: +26.26%
Definium Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $65
Current: $40.25
Upside: +61.49%
Axsome Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $380
Current: $216.58
Upside: +75.45%
Biogen
Jul 30, 2026
Reiterated: Buy
Price Target: $255
Current: $217.36
Upside: +17.32%
Praxis Precision Medicines
Jun 30, 2026
Reiterated: Buy
Price Target: $550
Current: $330.55
Upside: +66.39%
COMPASS Pathways
May 14, 2026
Reiterated: Buy
Price Target: $18
Current: $14.54
Upside: +23.80%
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $145
Current: $63.38
Upside: +128.78%
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $58.19
Upside: +71.85%
Jan 12, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $20.92
Upside: +43.40%
Dec 31, 2025
Reiterated: Hold
Price Target: $7.5
Current: $5.15
Upside: +45.63%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.2432
Upside: +270.07%
Nov 24, 2025
Reiterated: Buy
Price Target: $30
Current: $29.60
Upside: +1.35%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $13.15
Upside: +143.35%
Nov 11, 2025
Reiterated: Buy
Price Target: $10
Current: $3.95
Upside: +153.16%
Aug 8, 2025
Reiterated: Hold
Price Target: $2.5 → $3
Current: $3.43
Upside: n/a
Aug 6, 2025
Reiterated: Hold
Price Target: $3 → $0.85
Current: $1.98
Upside: n/a
Mar 26, 2025
Reiterated: Buy
Price Target: $8.5
Current: $5.34
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $41.49
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $44.00
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $7.47
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $4.44
Upside: n/a